secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensus Healthcare, Inc. (SRTS)
CIK:        0001494891
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001213900-24-011598
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensus Healthcare Q4 revenue $12.6M, net income $4.2M; introduces recurring revenue model
--------------------------------------------------------------------------------

- Q4 revenue $12.6M (vs $13.1M YoY) but up 3x sequentially from Q3 $3.9M; net income $4.2M ($0.26 diluted EPS) vs $2.8M YoY.
- Full-year 2023 net income positive at $0.03 diluted EPS; shipped 66 SRT units (33 in Q4). Cash $23.1M, no debt.
- Introduced recurring revenue model for SRT-100 Vision; first placement completed with multiple in pipeline.
- Appointed President & General Counsel Michael Sardano to Board of Directors.
- Engaged CureRays for clinical oversight and studies to expand SRT indications beyond skin cancer and keloids.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1494891/000121390024011598/0001213900-24-011598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1494891/000121390024011598/ea193048-8k_sensus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-011598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer